Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Income (2016 - 2025)

Iovance Biotherapeutics has reported Operating Income over the past 13 years, most recently at -$73.5 million for Q4 2025.

  • Quarterly results put Operating Income at -$73.5 million for Q4 2025, up 15.15% from a year ago — trailing twelve months through Dec 2025 was -$403.4 million (down 2.04% YoY), and the annual figure for FY2025 was -$403.4 million, down 2.04%.
  • Operating Income for Q4 2025 was -$73.5 million at Iovance Biotherapeutics, up from -$94.9 million in the prior quarter.
  • Over the last five years, Operating Income for IOVA hit a ceiling of -$73.5 million in Q4 2025 and a floor of -$121.3 million in Q4 2023.
  • Median Operating Income over the past 3 years was -$110.5 million (2023), compared with a mean of -$104.9 million.
  • Biggest five-year swings in Operating Income: grew 28.6% in 2024 and later decreased 11.64% in 2025.
  • Iovance Biotherapeutics' Operating Income stood at -$121.3 million in 2023, then rose by 28.6% to -$86.6 million in 2024, then increased by 15.15% to -$73.5 million in 2025.
  • The last three reported values for Operating Income were -$73.5 million (Q4 2025), -$94.9 million (Q3 2025), and -$113.8 million (Q2 2025) per Business Quant data.